OTCMKTS:QBIO

Q BioMed (QBIO) Stock Forecast, Price & News

$0.11

-0.04 (-26.67%)

(As of 05/13/2022 03:47 PM ET)

Add

Compare

Today's Range: $0.11
▼
$0.14
50-Day Range: $0.11
▼
$0.31
52-Week Range: $0.11
▼
$1.06

Volume: 162,100 shs
Average Volume: 120,032 shs
Market Capitalization: $3.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 1.43

30 days | 90 days | 365 days | Advanced Chart

Receive QBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

About Q BioMed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

May 11, 2022 | investing.com

Q BioMed Inc (QBIO)

May 6, 2022 | proactiveinvestors.com

Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets

May 6, 2022 | finance.yahoo.com

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets

April 24, 2022 | americanbankingnews.com

Q BioMed (OTCMKTS:QBIO) Shares Down 8.9%

March 16, 2022 | proactiveinvestors.com

Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer

March 16, 2022 | finance.yahoo.com

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer

March 7, 2022 | seekingalpha.com

Q BioMed expands Strontium89 to Chinese market with $500K order

March 7, 2022 | finance.yahoo.com

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

February 14, 2022 | proactiveinvestors.com

Q BioMed outlines strategic direction and goals for 2022

February 14, 2022 | finance.yahoo.com

Q BioMed Outlines Strategic Direction for 2022

December 16, 2021 | proactiveinvestors.com

Q BioMed says it is seeing a ‘significant uptrend’ in revenues as it continues to roll out Strontium89

December 16, 2021 | proactiveinvestors.com

NA Proactive news snapshot: Q BioMed Inc, FansUnite Entertainment Inc, BioSig Technologies Inc, Endexx Corporation, Doré Copper ...

December 16, 2021 | finance.yahoo.com

Q BioMed Shows Significant Uptrend in Revenues in Year-End Update

See More Headlines

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:QBIO
Previous Symbol: NASDAQ:QBIO
CUSIP: N/A
CIK: 1596062
Web: www.qbiomed.com
Phone: (646) 889-2226
Fax: N/A
Employees: 3
Year Founded: N/A

Sales & Book Value

Annual Sales: $200 thousand
Price / Sales: 19.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.37) per share
Price / Book: -0.30

Profitability

EPS (Most Recent Fiscal Year): ($0.310010)
Net Income: $-8.24 million
Net Margins: -2,971.96%
Pretax Margin: -2,972.32%
Return on Equity: N/A
Return on Assets: -1,178.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.03
Quick Ratio: 0.03

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 34,951,000
Free Float: N/A
Market Cap: $3.84 million
Optionable: Not Optionable

Company Calendar

Last Earnings: 4/14/2022
Today: 5/16/2022
Fiscal Year End: 11/30/2022

MarketRank^™

Overall MarketRank^™

0.91 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Q BioMed.

4.5 Community Rank

Outperform Votes
Q BioMed has received 147 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Q BioMed has received 70 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Q BioMed has received 67.74% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Q BioMed and other stocks. Vote “Outperform” if you believe QBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Q BioMed does not currently pay a dividend.
Dividend Growth
Q BioMed does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Q BioMed insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 10.02% of the stock of Q BioMed is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Q BioMed is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Q BioMed is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Q BioMed (OTCMKTS:QBIO) Frequently Asked Questions

Are investors shorting Q BioMed?: Q BioMed saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 3,600 shares, a decline of 91.5% from the April 15th total of 42,600 shares. Based on an average trading volume of 602,300 shares, the short-interest ratio is currently 0.0 days.
View Q BioMed's Short Interest.
How were Q BioMed's earnings last quarter?: Q BioMed Inc. (OTCMKTS:QBIO) announced its earnings results on Thursday, April, 14th. The company reported ($0.08) earnings per share for the quarter. The firm earned $0.08 million during the quarter.
View Q BioMed's earnings history.
Who are Q BioMed's key executives?: Q BioMed's management team includes the following people:
Mr. Denis D. Corin, Chairman, CEO & Pres (Age 49, Pay $300k)
Mr. William S. Rosenstadt, Chief Legal Officer, Gen. Counsel & Director (Age 54, Pay $300k)
Mr. David Laskow-Pooley, VP of Product Devel. (Age 68)
Mr. Robert Derham, VP of Orphan Products
Mr. Ari Jatwes, Bus. Devel. Analyst
Dr. Amy Ripka, Medicinal Chemistry Advisor
Who are some of Q BioMed's key competitors?: Some companies that are related to Q BioMed include Diffusion Pharmaceuticals (DFFN), Galmed Pharmaceuticals (GLMD), Exicure (XCUR), Alterity Therapeutics (ATHE), NanoViricides (NNVC), NanoViricides (NNVC), Celsion (CLSN), Tenax Therapeutics (TENX), Sycamore Entertainment Group (SEGI), Cingulate (CING), Artelo Biosciences (ARTL), NeuroSense Therapeutics (NRSN), Cyclacel Pharmaceuticals (CYCC), Evofem Biosciences (EVFM) and Novelion Therapeutics (NVLNF).
View all of QBIO's competitors.
What other stocks do shareholders of Q BioMed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), (CGC), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T).
What is Q BioMed's stock symbol?: Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO."
How do I buy shares of Q BioMed?: Shares of QBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Q BioMed's stock price today?: One share of QBIO stock can currently be purchased for approximately $0.11.
How much money does Q BioMed make?: Q BioMed has a market capitalization of $3.84 million and generates $200 thousand in revenue each year. The company earns $-8.24 million in net income (profit) each year or ($0.310010) on an earnings per share basis.
How many employees does Q BioMed have?: Q BioMed employs 3 workers across the globe.
What is Q BioMed's official website?: The official website for Q BioMed is www.qbiomed.com.
How can I contact Q BioMed?: Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The company can be reached via phone at (646) 889-2226.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.